Science, Teamwork and Support: Novartis collaborates with Patient Advocates for Sarcoma Awareness Month
Jul 27, 2017
July is not only a month for celebration and summer holidays it’s also an important time to honor those affected by soft tissue sarcoma (STS) around the world. At Novartis, we are proud to join the Sarcoma Awareness Month global initiative to help increase awareness of this disease.
Soft tissue sarcoma is a malignant tumor of connective tissue, accounting for about 1% of all human cancers. Unfortunately for many patients, their disease may progress to an advanced or metastatic stage. As a company, we are committed to providing resources that can help people better understand the disease and support the needs of those who live with it. That is why we collaborated with patient advocates to get their perspectives and thoughts on how we can all work together to help raise awareness. To learn more, watch our video here: [http://bit.ly/2h0fVjw].
Science: There are more than 50 soft tissue sarcoma subtypes. The most common among adults in the U.S. are leiomyosarcoma (46.5%), undifferentiated pleomorphic sarcoma (16%) and liposarcoma (25.8%). STS is considered advanced, or metastatic, when it spreads beyond the soft tissues into other parts of the body1.
Some signs and symptoms of advanced STS may include, but are not limited to2:
Increasing abdominal pain
Blood in the stool or vomit
A new lump or a lump that is growing (anywhere in the body)
Black, tarry stool
Support: You are not alone and together we can make a difference. Novartis remains dedicated to providing patients with rare cancers, such as STS, materials and resources to guide them through their journey. Support groups and advocacy information can be found here: [http://bit.ly/2tFHv75]
Teamwork: Treatment of STS usually is managed by a multidisciplinary team, including pathologists, radiologists, surgeons, radiation therapists and medical oncologists, as well as nuclear medicine specialists and specialists in the specific organ involved. By educating the public about STS, we can create a cohesive sarcoma community where patients can have an influential voice and spread the word about sarcoma. A medical expert recently stated the biggest struggle for those affected by the disease is a lack of knowledge and awareness of the disease. It is important for further education and resources to help those the disease affects.
The patient advocacy community inspires us to remain dedicated to the research, development and delivery of innovative treatments to help improve care for those living with and managing STS. Watch our video and to learn more, you may find additional information on soft tissue sarcoma.
Leahy M, Garcia del Muro X, Reichardt P, et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study. Ann of Onc. 2012;23:2763-2770.